Literature DB >> 10417764

Mass-spectrometric evaluation of HLA-A*0201-associated peptides identifies dominant naturally processed forms of CTL epitopes from MART-1 and gp100.

J C Skipper1, P H Gulden, R C Hendrickson, N Harthun, J A Caldwell, J Shabanowitz, V H Engelhard, D F Hunt, C L Slingluff.   

Abstract

Melanoma-reactive human cytotoxic T lymphocytes (CTLs) mediate tumor regression in vivo through specific recognition of MHC-associated peptide epitopes, many of which are encoded by the melanocytic tissue differentiation proteins gp100/Pme117 and MART-1/Melan-A. Vaccines using these peptides may induce protective or therapeutic immunity against melanoma. Rational design of such approaches is aided by a clear understanding of the identity of these antigenic peptides; however, most CTL epitopes described to date were identified indirectly. Especially where these peptides may be used in human clinical trials for the treatment or prevention of cancer, there is substantial need for direct evaluation of HLA-A*0201-associated peptides from MART-1 and gp100 that are naturally processed and presented. To that end, we have isolated peptides directly from HLA-A*0201 molecules of human melanoma cells and have determined that naturally processed epitopes for HLA-A*0201-restricted, melanoma-reactive CTLs include the nonamers MART-1(27-35) (AAGIGILTV), gp100(154-162) (KTWGQYWQV), gp100(209-217) (ITDQVPFSV) and gp100(280-288) (YLEPGPVTA) and the decamer gp100(476-485) (VLYRYGSFSV). Among these, the one that appears to be most abundant at the cell surface is gp100(154-162) (KTWGQYWQV). The others are among the less abundant peptides. HLA-A*0201-restricted CTLs from one melanoma patient who has survived metastatic disease recognized MART-1(27-35) (AAGIGILTV), gp100(280-288) (YLEPGPVTA) and gp100(154-162) (KTWGQYWQV) and were cross-reactive on longer peptides that contained these nonamer sequences. These peptides, identified by both an indirect genetic approach and by a direct peptide approach, can be used for tumor vaccine strategies with confidence that they are identical to the naturally processed peptide epitopes presented at the surface of melanoma cells in association with HLA-A*0201 molecules. Copyright 1999 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10417764     DOI: 10.1002/(sici)1097-0215(19990827)82:5<669::aid-ijc9>3.0.co;2-#

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  23 in total

1.  Loss of T cell antigen recognition arising from changes in peptide and major histocompatibility complex protein flexibility: implications for vaccine design.

Authors:  Francis K Insaidoo; Oleg Y Borbulevych; Moushumi Hossain; Sujatha M Santhanagopolan; Tiffany K Baxter; Brian M Baker
Journal:  J Biol Chem       Date:  2011-09-21       Impact factor: 5.157

2.  Adoptive transfer of vaccine-induced peripheral blood mononuclear cells to patients with metastatic melanoma following lymphodepletion.

Authors:  Daniel J Powell; Mark E Dudley; Katherine A Hogan; John R Wunderlich; Steven A Rosenberg
Journal:  J Immunol       Date:  2006-11-01       Impact factor: 5.422

Review 3.  MHC class I antigen presentation and implications for developing a new generation of therapeutic vaccines.

Authors:  Joseph D Comber; Ramila Philip
Journal:  Ther Adv Vaccines       Date:  2014-05

4.  TCRs used in cancer gene therapy cross-react with MART-1/Melan-A tumor antigens via distinct mechanisms.

Authors:  Oleg Y Borbulevych; Sujatha M Santhanagopolan; Moushumi Hossain; Brian M Baker
Journal:  J Immunol       Date:  2011-07-27       Impact factor: 5.422

5.  Structures of MART-126/27-35 Peptide/HLA-A2 complexes reveal a remarkable disconnect between antigen structural homology and T cell recognition.

Authors:  Oleg Y Borbulevych; Francis K Insaidoo; Tiffany K Baxter; Daniel J Powell; Laura A Johnson; Nicholas P Restifo; Brian M Baker
Journal:  J Mol Biol       Date:  2007-07-26       Impact factor: 5.469

6.  Wnt5A regulates expression of tumor-associated antigens in melanoma via changes in signal transducers and activators of transcription 3 phosphorylation.

Authors:  Samudra K Dissanayake; Purevdorj B Olkhanud; Michael P O'Connell; Arnell Carter; Amanda D French; Tura C Camilli; Chineye D Emeche; Kyle J Hewitt; Devin T Rosenthal; Poloko D Leotlela; Michael S Wade; Sherry W Yang; Larry Brant; Brian J Nickoloff; Jane L Messina; Arya Biragyn; Keith S Hoek; Dennis D Taub; Dan L Longo; Vernon K Sondak; Stephen M Hewitt; Ashani T Weeraratna
Journal:  Cancer Res       Date:  2008-12-15       Impact factor: 12.701

7.  Phase I clinical trial of the vaccination for the patients with metastatic melanoma using gp100-derived epitope peptide restricted to HLA-A*2402.

Authors:  Toshiyuki Baba; Marimo Sato-Matsushita; Akira Kanamoto; Akihiko Itoh; Naoki Oyaizu; Yusuke Inoue; Yutaka Kawakami; Hideaki Tahara
Journal:  J Transl Med       Date:  2010-09-16       Impact factor: 5.531

8.  Phenotypic and functional maturation of tumor antigen-reactive CD8+ T lymphocytes in patients undergoing multiple course peptide vaccination.

Authors:  Daniel J Powell; Steven A Rosenberg
Journal:  J Immunother       Date:  2004 Jan-Feb       Impact factor: 4.456

9.  IL-12p70-producing patient DC vaccine elicits Tc1-polarized immunity.

Authors:  Beatriz M Carreno; Michelle Becker-Hapak; Alexander Huang; Megan Chan; Amer Alyasiry; Wen-Rong Lie; Rebecca L Aft; Lynn A Cornelius; Kathryn M Trinkaus; Gerald P Linette
Journal:  J Clin Invest       Date:  2013-07-11       Impact factor: 14.808

10.  Targeting human melanoma neoantigens by T cell receptor gene therapy.

Authors:  Matthias Leisegang; Thomas Kammertoens; Wolfgang Uckert; Thomas Blankenstein
Journal:  J Clin Invest       Date:  2016-01-25       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.